Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 10/20 | 0.44 |
| ▸ | PPARG | P37231 | 10/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032327 | 0.93 | PPARG (0.49) | FFAR1PPARAPPARGPPARD | |
| SCHEMBL4034732 | 0.86 | FFAR1 (0.58) | FFAR1PPARAPPARGPPARDMAPT | |
| SCHEMBL4030253 | 0.81 | PPARG (0.45) | FFAR1PPARAPPARGPPARD | |
| SCHEMBL4035125 | 0.81 | FFAR1 (0.56) | FFAR1PPARAPPARGPPARDMAPT | |
| SCHEMBL4027344 | 0.81 | FFAR1 (0.54) | FFAR1PPARAPPARGPPARD | |
| SCHEMBL4028583 | 0.81 | FFAR1 (0.63) | FFAR1PPARAPPARGPPARDMAPT | |
| SCHEMBL4026030 | 0.81 | FFAR1 (0.55) | FFAR1PPARAPPARGPPARDMAPT | |
| SCHEMBL4025236 | 0.80 | PPARA (0.64) | FFAR1PPARAPPARGPPARDMAPT | |
| SCHEMBL4030193 | 0.80 | PPARG (0.58) | FFAR1PPARAPPARGMAPT | |
| SCHEMBL4030711 | 0.80 | PPARA (0.67) | FFAR1PPARAPPARGPPARDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | claimed |
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | claimed |
| US-20060142277-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED | 2006-06-29 | — | — | US | claimed |
| EP-1569916-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD. (IN) | 2005-09-07 | — | — | EP | claimed |
| WO-2004046119-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2004-06-03 | — | — | WO | claimed |
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | disclosed |
| US-20060142277-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142277-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | FFAR1 2147/4885AKR1B1 202/4885PPARA 2339/4885 |
| US-20090275565-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | FFAR1 2147/4885AKR1B1 202/4885PPARA 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.